助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   np regimens 的翻译结果: 查询用时:0.009秒
图标索引 在分类学科中查询
所有学科
肿瘤学
更多类别查询

图标索引 历史查询
 

np regimens
    很抱歉,暂未找到该词条的译词。
相关语句
  “np regimens”译为未确定词的双语例句
     Methods CP or NP regimens were used. CP regimen involved CTX 0.8 g in 40 ml normal saline by iv injection and DDP 100 mg/m~(2)by abdominal infusion on the first day.
     方法CP方案为环磷酰胺(CTX)0.8 g加入生理盐水40 m l内静推,第1天,顺铂(DDP)100 mg/m2腹腔内注入,第1天;
短句来源
     30 patients in control group accepted NP regimens for 4cycles(21 days to be a cycle): NVB 30mg/m~2, iv, d1、 8;
     偏于气虚的,配合参芪扶正注射液,250ml,每日一次静脉滴注,连用20天为一疗程,每30天重复,连用4个疗程。
短句来源
     [Conclusion]Better but similar therapeutic efficacy has been obtained in patients with RMBC treated by TA and NP regimens. Although the median duration of survival in TA group seems rather longer than in NP group,there is no statistical significance yet.
     [结论]TA和NP两组方案治疗复发转移性乳腺癌疗效高且相似,但两组无统计学意义。
短句来源
     Objective To evaluate the short-time effects and toxic side-effects of EP, GP, NP regimens for patients with advanced Non-small Cell Lung Cancer (NSCLC).
     目的比较EP、GP、NP三种不同的化疗方案治疗非小细胞肺癌(NSCLC)的近期疗效和毒副反应。
短句来源
     AIM: To observe the effect and toxicity of NA and NP regimens for advanced breast cancer.
     目的:评价NA、NP两种化疗方案治疗晚期乳腺癌的疗效及毒副反应.
短句来源
  相似匹配句对
     ,…,Np(.)
     ,…,Np(.)
短句来源
     On the Issue of P and NP
     谈谈P和NP问题
短句来源
     Conclusion Both ITP and NP regimens are effective for the advanced NSCLC.
     结论 ITP和NP方案是治疗晚期NSCLC较有效的方案。
短句来源
     Comparison between NP and IAP regimens in treatment of patients with advanced NSCLC
     NP方案与IAP方案治疗晚期非小细胞肺癌的临床疗效对比研究
短句来源
     Comparison of Helicobacter pylori eradicative regimens
     幽门螺杆菌根除治疗方案比较
短句来源
查询“np regimens”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
没有找到相关例句


Objective: To compare the efficacy and toxicity in the treatment of non-small-cell lung cancer (NSCLC) with NP and MVP regimen Methods: Through every 21 to 28 days cycle, systemic administration of NP and MVP combination chemotherapeutic regimen, a total of 246 cases of advanced stage non-small-cell lung cancer were enrolled Among them, 159 cases were adenocarcinoma, 55 squamous cell carcinoma and 32 others Chemotherapy-naive patients account for 177 cases and 69 recurrent diseases...

Objective: To compare the efficacy and toxicity in the treatment of non-small-cell lung cancer (NSCLC) with NP and MVP regimen Methods: Through every 21 to 28 days cycle, systemic administration of NP and MVP combination chemotherapeutic regimen, a total of 246 cases of advanced stage non-small-cell lung cancer were enrolled Among them, 159 cases were adenocarcinoma, 55 squamous cell carcinoma and 32 others Chemotherapy-naive patients account for 177 cases and 69 recurrent diseases Results: The response rate were 35 7%(35/98) for NP regimen and 34 5%(51/148) for MVP regimen respectively There was no statistical significant difference ( P >0 05) between them Median time to progression were 5 months for NP and 4 months for MVP Median survival time were 11 months for NP and 8 months for MVP There was no significant difference ( P >0 05) for both of them between two groups The major toxicity was bone marrow suppression Grade Ⅲ~Ⅳleukopenia occurred in 50%of the NP group and 38 5%of the MVP group There was a significant difference ( P < 0 05) between two groups Grade Ⅲ~Ⅳthrombocytopenia was 4 1%in NP group and 7 4%in MVP group ( P >0 05) In grade Ⅲ~Ⅳ, nausea and vomiting were observed in 15 3%with NP and 18 2%with MVP ( P >0 05) and mainly occurred with grade Ⅲtoxicity in both groups Conclusion: Higher but similar response rates were seen in patients with NSCLC treated with NP and MVP regimens The median survival, although not significant was in favor of NP regimen Significant leukopenia occurred but was all tolerated well

目的 :对比NP和MVP两组方案治疗晚期非小细胞肺癌的疗效和毒性。方法 :通过NP和MVP两个联合化学治疗方案每 2 1~ 2 8天周期全身给药的方法共收治晚期非小细胞肺癌 2 46例 ,其中腺癌 15 9例 ,鳞癌 5 5例 ,其他 32例。初治 177例 ,复治 6 9例。结果 :NP组和MVP组有效率分别为 35 7% (35 / 98)和 34 5 % (5 1/ 148) ,两组无显著性差异 (P >0 0 5 )。中位缓解期NP组为 5个月 ,MVP组为 4个月 ;中位生存期NP组为 11个月 ,MVP组为 8个月 ,均无显著性差异。毒副作用主要是骨髓抑制。Ⅲ~Ⅳ度白细胞下降率NP组为 5 0 0 % ,MVP组为 38 5 % ,两组间有显著差异 (P <0 0 5 ) ,Ⅲ~Ⅳ度血小板下降率NP组为 4 1% ,MVP组为 7 4% (P >0 0 5 )。Ⅲ~Ⅳ度消化道反应两组发生率分别为 15 3%和 18 2 %且以Ⅲ度为主。结论 :NP和MVP两方案治疗晚期非小细胞肺癌有效率较高且相似 ,中位生存期虽无明显差异但NP方案较长。白细胞下降的副反应虽有差异性但均可耐受。因此 ...

目的 :对比NP和MVP两组方案治疗晚期非小细胞肺癌的疗效和毒性。方法 :通过NP和MVP两个联合化学治疗方案每 2 1~ 2 8天周期全身给药的方法共收治晚期非小细胞肺癌 2 46例 ,其中腺癌 15 9例 ,鳞癌 5 5例 ,其他 32例。初治 177例 ,复治 6 9例。结果 :NP组和MVP组有效率分别为 35 7% (35 / 98)和 34 5 % (5 1/ 148) ,两组无显著性差异 (P >0 0 5 )。中位缓解期NP组为 5个月 ,MVP组为 4个月 ;中位生存期NP组为 11个月 ,MVP组为 8个月 ,均无显著性差异。毒副作用主要是骨髓抑制。Ⅲ~Ⅳ度白细胞下降率NP组为 5 0 0 % ,MVP组为 38 5 % ,两组间有显著差异 (P <0 0 5 ) ,Ⅲ~Ⅳ度血小板下降率NP组为 4 1% ,MVP组为 7 4% (P >0 0 5 )。Ⅲ~Ⅳ度消化道反应两组发生率分别为 15 3%和 18 2 %且以Ⅲ度为主。结论 :NP和MVP两方案治疗晚期非小细胞肺癌有效率较高且相似 ,中位生存期虽无明显差异但NP方案较长。白细胞下降的副反应虽有差异性但均可耐受。因此 ,从不同的需要和考虑出发 ,两者均可作为治疗晚期非小细胞肺癌的首选方案。

Objective To evaluate effect of navelbine on non small cell lung cancer (NSCLC). Methods Forty eight cases of cytologically and pathologically confirmed advanced NSCLC were treated with combined chemotherapy including navelbine as the cardinal drug from May, 1995 to January, 1988. They were randomly divided into two groups. One group of 20 cases was treated with NP regimen (NVB+PDD); the other group of 28 cases was treated with NI regimen (NVB+IFO). All patients received no previous treatment....

Objective To evaluate effect of navelbine on non small cell lung cancer (NSCLC). Methods Forty eight cases of cytologically and pathologically confirmed advanced NSCLC were treated with combined chemotherapy including navelbine as the cardinal drug from May, 1995 to January, 1988. They were randomly divided into two groups. One group of 20 cases was treated with NP regimen (NVB+PDD); the other group of 28 cases was treated with NI regimen (NVB+IFO). All patients received no previous treatment. Results There was no complete response in patients treated with either regimen. Partial response was observed in 8 of 20 NP treated patients(40.0%) and in 12 of 28 NI treated patients (42.8%). There was no statistical difference in response rate between these 2 groups of NSCLC patients, However, in both groups of patients, the therapeutic effect was better in adenocarcinoma than in sequamous cell carcinoma patients. NP regimen seemed effective in the control of bone metastases and pains. Side effects were mainly myelo suppression and digestive tract reaction. Conclusion Combined chemotherapy including NVB is worthy of use in the treatment of advanced NSCLC especially for those with bone metastasis.

目的评价去甲去氢长春碱(诺维本,NVB)对非小细胞肺癌(NSCLC)的治疗作用。方法采用诺维本为主药的联合方案治疗非小细胞肺癌48例,均为初治患者,均经细胞学或病理证实。结果本组48例中,没有完全缓解病例,部分缓解20例,有效率为41.7%,其中腺癌有效率为53.5%,鳞癌有效率为25.0%,其差异有显著性。NP方案:诺维本(NVB)+顺铂(PDD)治疗20例,有效率为40.0%;NI方案:NVB+IFO(异环磷酰胺)治疗28例,有效率为42.8%,两方案差异无显著性。它不仅能使肿块缩小、缓解症状,而且对骨转移性疼痛及溶骨性破坏疗效更好。对肺鳞癌加上放疗,将获得更好的效果。主要毒性为骨髓抑制及消化道反应。结论NP或NI方案是治疗非小细胞肺癌,尤其是合并骨转移者较为理想的方案。

Objective:To evaluate the curative effects of NP(NVB+ PDD) regimen and MVP (MMC + VDS + PDD) regimen on advanced non - small cell lung cancer. Methods:63 cases of advanced non - small cell lung cancer who firstly received chemothera-py were randomly divided into two groups. NP regimen consisted of NVB 25~30mg/m2(dl?d5 iv drop), PDD 50mg(d2?d3 iv drop) . MVP regimen consisted of MMC 6mg/m2(d1 iv), VDS 3mg/m2(dl ?d8 iv drop), PDD 50mg(d2?d3 iv drop), every 3 weeks for at least two...

Objective:To evaluate the curative effects of NP(NVB+ PDD) regimen and MVP (MMC + VDS + PDD) regimen on advanced non - small cell lung cancer. Methods:63 cases of advanced non - small cell lung cancer who firstly received chemothera-py were randomly divided into two groups. NP regimen consisted of NVB 25~30mg/m2(dl?d5 iv drop), PDD 50mg(d2?d3 iv drop) . MVP regimen consisted of MMC 6mg/m2(d1 iv), VDS 3mg/m2(dl ?d8 iv drop), PDD 50mg(d2?d3 iv drop), every 3 weeks for at least two cycles. Results: 33 cases were treated with NP regimen, 30 cases with MVP regimen. The results showed that the re-sponse rates of NP regimen and MVP regimen were 51.5% (17/33) and 46.67(14/30) respectively. There was no statistical signifi-cant difference between them (P>0.05) . In NP group, there were 3 cases showing complete remission. The main toxicity were myelosuppressian. The NP regimen was more seroius than MVP regimen. The NP regimen mainly caused the third degree of myelo-suppression. There was statistical significant difference(P<0.05). Conclusion: It is concluded that both NP regimen and MVP regi-men may be used as first - line regimens for the treatment of advanced non - small cell lung cancer.

目的:对比NP方案和MVP方案治疗晚期NSCLC的疗效.方法:63例首次化疗的晚期NSCLC病人,依住院的先后顺序随机分为NP组和MVP组.NP方案:NVB25~30mg/m~2d1、d5iv,PDD 50mg d2、d3 iv drop.MVP方案:MMC6mg/m~2 d_1 iv,VDS 3mg/m~2 d1、d8 iv drop,PDD用法同NP方案.21天为一周期,满二个周期者进行疗效评估.结果:NP组有效率为51.5%(17/33),其中3例达到完全缓解;MVP组有效率为46.67%(14/30),两组疗效差异无显著意义(P>0.05).副作用均主要为骨髓抑制,NP组所致骨髓抑制多为Ⅲ度,两组间有显著差异(P<0.05).结论:NP方案和MVP方案可做为晚期NSCLC的一线化疗方案.

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关np regimens的内容
在知识搜索中查有关np regimens的内容
在数字搜索中查有关np regimens的内容
在概念知识元中查有关np regimens的内容
在学术趋势中查有关np regimens的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社